article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

We received encouraging feedback from the US Food and Drug Administration (FDA) on the trial design and potential for accelerated approval. We also believe that bispecifics will further establish themselves as an important drug class in the treatment regimens for both haematological malignancies and solid tumours.

article thumbnail

Reality Bites: Disappointment in the R&D Sector

Pharmaceutical Technology

As the blockbuster drugs of the 90s that earned the industry billions reach their patent shelf lives, pharmaceutical companies require new medicines to sustain an estimated $157bn worth of sales. Even so, current figures show firms’ biggest portion of spend is still on marketing and administration at 33.1%,

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. When the balloon reaches a sufficient pressure, this pushes the dissolvable needle into the intestinal wall, delivering the drug payload.”